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A B S T R A C T
Gallbladder mucocele (GBM) is a common extra-hepatic biliary syndrome in dogs with death rates
ranging from 7 to 45%. Therefore, the aim of this study was to identify the association of survival with
variables that could be utilized to improve clinical decisions. A total of 1194 dogs with a gross and
histopathological diagnosis of GBM were included from 41 veterinary referral hospitals in this
retrospective study.
Dogs with GBM that demonstrated abnormal clinical signs had signiﬁcantly greater odds of death than
subclinical dogs in a univariable analysis (OR, 4.2; 95% CI, 2.14–8.23; P < 0.001). The multivariable model
indicated that categorical variables including owner recognition of jaundice (OR, 2.12; 95% CI, 1.19–3.77;
P = 0.011), concurrent hyperadrenocorticism (OR 1.94; 95% CI, 1.08–3.47; P = 0.026), and Pomeranian
breed (OR, 2.46; 95% CI 1.10–5.50; P = 0.029) were associated with increased odds of death, and vomiting
was associated with decreased odds of death (OR, 0.48; 95% CI, 0.30–0.72; P = 0.001). Continuous
variables in the multivariable model, total serum/plasma bilirubin concentration (OR, 1.03; 95% CI, 1.01–
1.04; P < 0.001) and age (OR, 1.17; 95% CI, 1.08–1.26; P < 0.001), were associated with increased odds of
death. The clinical utility of total serum/plasma bilirubin concentration as a biomarker to predict death
was poor with a sensitivity of 0.61 (95% CI, 0.54–0.69) and a speciﬁcity of 0.63 (95% CI, 0.59–0.66). This
study identiﬁed several prognostic variables in dogs with GBM including total serum/plasma bilirubin
concentration, age, clinical signs, concurrent hyperadrenocorticism, and the Pomeranian breed. The
presence of hypothyroidism or diabetes mellitus did not impact outcome in this study.
© 2019 Elsevier Ltd. All rights reserved.Introduction
Gallbladder mucocele (GBM) in dogs is deﬁned as a distended
gallbladder with an abnormal accumulation of thick amorphous
mucin in conjunction with histologic evidence of mucosal
hypertrophy, formation of mucus-ﬁlled cysts, and long, thin
branching fronds of well differentiated gallbladder epithelial cells
(Gookin et al., 2015; Kesimer et al., 2015; Pike et al., 2004; Stalker
et al., 2007). The syndrome has emerged as one of the most
commonly identiﬁed causes of biliary disease in dogs over the last
10 years (Gookin et al., 2015). The clinical importance of GBM
relates to the morbidity and mortality associated with extrahepatic
biliary duct obstruction, gallbladder rupture, biliary infection, and
systemic inﬂammatory response syndrome that can occur
secondary to gallbladder wall necrosis, infarction, or perforation
(Jaffey et al., 2018).
The optimal time for surgical intervention in dogs with GBM that
demonstrate clinical signs associated with biliary tract disease has not
beendeﬁned.Overthelast20yearstherehasbeenashifttowardsearly
surgical intervention inpeoplewith acutecholecystitis (Loet al.,1998).
Performing cholecystectomy in people with acute cholecystitis within
72 h of time of onset of symptoms signiﬁcantly decreases the overall
incidence of complications, including perioperative blood loss, length
ofhospital stay,woundinfection,overall morbidity,andmortality(Cao
et al., 2016; Gonzalez-Rodriguez et al., 2009; Lau et al., 2006). While
not directly comparable to canine GBM, some of these concerns
regarding cholecystitis in people are likely to be of relevance,
particularly as cholecystitis and regional inﬂammation has been
observed in some dogs with GBM (Malek et al., 2013; Pike et al., 2004;
Tamborini et al., 2016; Wennogle et al., 2019; Rogers et al., 2019).The average time from the onset of clinical signs to surgery in
dogs with GBM according to one small study is approximately 8
days (Worley et al., 2004). However, the relationship between
timing of cholecystectomy and outcome has not been investigated
in dogs with GBM. Furthermore, there is limited information
related to the impact of abnormal clinical signs associated with
biliary tract disease in dogs with GBM on survival. In a recent
retrospective study, dogs that demonstrated one or more clinical
sign attributable to biliary tract disease had a signiﬁcantly greater
mortality rate than dogs that were subclinical at the time of
cholecystectomy (Youn et al., 2018). However, this study did not
investigate the effect of speciﬁc clinical signs and survival in a
multivariable model.
Hyperbilirubinemia is reported to occur in approximately 52%–
100% of dogs with GBM (Crews et al., 2009; Malek et al., 2013; Youn
et al., 2018). Hyperbilirubinemia is a preoperative risk factor for
death in dogs undergoing biliary surgery and total serum/plasma
bilirubin concentrations predict a shorter survival time in Shetland
sheepdogs with gallbladder disease and in dogs with acute and
chronic hepatopathies (Aguirre et al., 2007; Amsellem et al., 2006;
Dereszynski et al., 2008; Ferguson et al., 2011; Gomez Selgas et al.,
2014; Kilpatrick et al., 2016; Lester et al., 2016; Poldervaart et al.,
2009). There is limited information regarding the utility of total
bilirubin concentration as a biomarker for survival in dogs with
GBM despite hyperbilirubinemia being a common clinicipatho-
logic abnormality in dogs with GBM and its association with
decreased survival in dogs with biliary surgery.
Chronic hypercortisolemia (Worley et al., 2004), hypothy-
roidism (Ekmektzoglou and Zografos, 2006; Ladenson et al.,
1984; Safer, 2013; Safer et al., 2004), and diabetes mellitus (DM;
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been shown to negatively impact wound healing and substan-
tially increase the risk of surgery-related morbidity and death in
a variety of species. Dogs with hyperadrenocorticism (i.e.
hypercortisolemia; Gookin et al., 2015; Mesich et al., 2009),
hypothyroidism (Mesich et al., 2009), and hyperlipidemia
(Kutsunai et al., 2014) have signiﬁcantly higher odds of having
a GBM. However, the possibility of an association between
hyperadrenocorticism, hypothyroidism, and hyperlipidemia and
outcome in dogs with GBM has not been evaluated. Under-
standing this relationship is clinically important because of how
common GBM occur in dogs with hyperadrenocorticism,
hypothyroidism, DM, and hyperlipidemia.
The present study had four objectives. The ﬁrst was to
determine if timing of cholecystectomy after recognition of clinical
signs impacted survival. Our second objective was to investigate if
there was a difference in outcome between dogs with or without
clinical signs attributable to GBM. The third objective was to
determine if a diagnosis of concurrent hyperadrenocorticism,
hypothyroidism, DM, or hyperlipidemia was associated with
increased death. The ﬁnal objective of our study was to evaluate
total serum/plasma bilirubin concentration as a prognostic
biomarker. We hypothesized that greater time (days) from initial
recognition of clinical signs to cholecystectomy in dogs with GBM
would be signiﬁcantly associated with death. Further, we
hypothesized that dogs with clinical signs attributable to GBM
at the time of cholecystectomy would be more likely to die than
dogs without clinical signs. Next, we hypothesized that dogs with
comorbidities (hyperadrenocorticism, hypothyroidism, DM, and
hyperlipidemia) would be more likely to die than dogs without
these comorbidities. Lastly, we hypothesized that total serum/
plasma bilirubin concentration could be used to predict death.
Materials and methods
Criteria for selection of cases
A retrospective, multi-center, case series was performed. Multiple institutions
throughout the United States of America, Canada, Australia, Asia, South America and
Europe were contacted for participation in this study. This was achieved by direct
communication via email with board-certiﬁed small animal internists with contact
information available in the American College of Veterinary Internal Medicine and
European College of Veterinary Internal Medicine – Companion Animal directory.
Only institutions with at least one boarded small animal specialist (i.e. internal
medicine, surgeon, clinical pathologist, or criticalist) were eligible for participation.
Medical records of dogs that had gross and histopathologic diagnosis of GBM after
cholecystectomy examined between January 2007 and January 2017 were
requested. Cases were identiﬁed at each institution by searching medical records,
histopathology and surgery logs for ‘gallbladder mucocele/mucocoele’, ‘mucocele/
mucocoele’, and ‘cholecystectomy’. Some data from this cohort was previously
reported in studies with different objectives (Allerton et al., 2018; Jaffey et al., 2018;
Rogers et al., 2019). This study was approved by the Clinical Research Ethical Review
Board of the University of Edinburgh (# 132.17; date of approval 11th November
2017) and University of Nottingham (# 2149.171108; date of approval 7th November
2017). The remaining institutions obtained dog owner signed consent on standard
hospital admission documents that outline permission for use of data from medical
records for research. All histologic interpretations were made by board-certiﬁed
veterinary pathologists or the equivalently trained expert as dictated by the
scientiﬁc standards of the geographic region. Likewise, all cholecystectomies were
performed by, or under the direct supervision of, a boarded-veterinary surgeon or
the equivalently trained expert as dictated by the scientiﬁc standards of the
geographic region.
The data retrieved from medical records included: beginning and ending dates
of medical records undergoing review; age; breed; sex; histologic features
consistent with GBM; time (days) from the onset of clinical signs to surgery;
description of clinical signs; the presence of hyperadrenocorticism, hypothyroid-
ism, DM, or combination thereof; treatment for hyperadrenocorticism, hypothy-
roidism, and DM; blood biochemical data (total bilirubin, triglyceride, and
cholesterol concentrations); survival to discharge; and cause of death. All
biochemical data were obtained during the hospitalization associated with
cholecystectomy or death.
A diagnosis of GBM was made based on gross appearance of a distended
gallbladder with an abnormal accumulation of thick amorphous mucin inconjunction with histologic evidence of mucosal hypertrophy, formation of
mucus-ﬁlled cysts, and long, thin branching fronds of well differentiated
gallbladder epithelial cells (Gookin et al., 2015; Kesimer et al., 2015; Pike et al.,
2004). A dog was considered to have hypothyroidism or hyperadrenocorticism if a
historical diagnosis was present at the time of cholecystectomy. A dog was
considered to have hypothyroidism if serum (total or free) T4 concentration was less
than the lower limit of the reference interval and concurrent serum TSH
concentration was greater than the upper limit of the reference interval of the
respective laboratory (Mesich et al., 2009). A dog was considered to have
hyperadrenocorticism if a low-dose dexamethasone suppression test or ACTH
stimulation test results were positive according to the laboratory-derived cutoffs
used for hyperadrenocorticism and consistent clinical signs were present (e.g.
polyuria, polydipsia, polyphagia, panting, abdominal distension; Mesich et al.,
2009). A dog was considered to have DM if a historical diagnosis was present or if
hyperglycemia, glucosuria, and clinical signs consistent with DM were identiﬁed at
the time of evaluation (Mesich et al., 2009). Hyperlipidemia was deﬁned as an
increase in the blood concentration of cholesterol, triglycerides, or both (De Marco
et al., 2017; Lee et al., 2017). Both cholesterol and triglyceride concentrations were
required to be less than the upper limit of each reference interval to rule out
hyperlipidemia in order to minimize potential false negatives related to missing
data for either parameter. Dogs were considered to have clinical signs attributable
to biliary tract disease if the owner reported vomiting, lethargy, anorexia,
hyporexia, pain, jaundice, diarrhea, hypodipsia, adipsia, weakness, fever, and
abdominal distension in the 7 days prior to presentation. Death-in-hospital was the
primary outcome of interest, and was deﬁned collectively, as in-hospital death or
euthanasia in dogs with GBM that had undergone a cholecystectomy. Survival after
hospital discharge was not assessed in this study.
Statistical analysis
Statistical analysis was performed using commercially available software
(STATA SE, v.15.1, StataCorp, College Station, TX). The Shapiro-Wilk test was used to
assess normality of continuous numerical variables. The data with non-normal
distribution were presented as median, Q1, Q3, and range. Analyses of total serum/
plasma bilirubin concentration were made based on the fold change with respect to
the upper limit of the corresponding reference interval (i.e. total serum/plasma
bilirubin concentration / upper limit of the reference interval). A receiver-operating
characteristic (ROC) curve was used to determine the area under the curve (AUC)
and select the optimum cut-off value of the fold change in total serum/plasma
bilirubin concentration for prediction of death-in-hospital that maximized the
Youden’s J statistic for sensitivity and speciﬁcity reporting.
Patient data were considered clustered within hospital; and all regression
models were ﬁtted as random-effects logit models with death as the binary
outcome of interest. Coefﬁcients in the models were exponentiated to produce odds
ratios. Numerical variables, age and duration of clinical signs before surgery, were
assessed in regression as continuous variables and also categorized into quartiles
and quintiles, respectively, based on natural breaks in the data. Model comparison
was based on Akaike information criteria (AIC) and Bayesian information criteria
(BIC), and for both variables analysis as continuous variables was chosen as
equivalent or superior to division into quartiles/quintiles.
Univariate random-effects logistic regression analyses were performed to
screen for the association between death and the independent variables of interest.
Comorbidities as hyperadrenocorticism, hypothyroidism, DM, hyperlipidemia,
hypercholesterolemia, hypertriglyceridemia were included in regression analyses
as dichotomous variables with absence of the comorbidity as the referent.
Covariates screened individually using univariable logistic regression and having a
liberal P-value cutoff, i.e. P < 0.20, were included in the ﬁnal multivariable analysis.
The level of signiﬁcance was set at P < 0.05 for the multivariable analysis, as well as
all other statistical tests, and only variables with P-values <0.05 were retained in the
ﬁnal reported model. Confounding was assessed by determining if individual
variable odds ratios changed by >20% with inclusion/removal of additional
variables.
Results
Animal population
A total of 1194 dogs from 38 academic veterinary hospitals and
3 private practice specialty hospitals in 20 countries were included
in the study. Collaborators were recruited through direct contact
with referral centers. Medical record system changes altered the
study period from four institutions (Supplemental Table S1). No
dogs were excluded.
There was a total of 1006 purebred dogs and 188 mixed breed
dogs (Supplemental Table S2). The most commonly represented
breeds (i.e. those comprising >30 dogs) were Mixed breed dogs,
Shetland sheepdog, Cocker spaniel, Miniature schnauzer, Bichon
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(Supplemental Table S1). The median age was 10 years (Q1, Q3,
range; 8.0, 12.0, 2.0–17.0 years). There were 546 spayed females,
496 castrated males, 86 intact males and 66 intact females.
All 1194 dogs had a cholecystectomy performed. Medical
records detailing the presence or absence of clinical signs
attributable to biliary tract disease (i.e. clinical or subclinical) at
the time of cholecystectomy were available for 99.9% (1193/1194)
dogs (Fig.1). A total of 17.6% (211/1194) of dogs did not exhibit
clinical signs at the time of cholecystectomy. The reason for
cholecystectomy was available for 84.8% (179/211) of dogs that
were subclinical. The indication for surgery in these 179 dogs
included prophylactic surgery after an incidental ultrasonographic
identiﬁcation of GBM in 62.6% (112/179), failure of improvement in
liver enzyme activities or lack of ultrasonographic resolution of
GBM after medical management in 12.8% (23) of dogs, and
concomitant increase in liver enzyme activities and ultrasono-
graphic identiﬁcation of GBM in 6.7% (12). A total of 17.9% (32/179)
of dogs had a planned cholecystectomy in conjunction with
another surgery or it was performed at the discretion of a surgeon
during an unrelated procedure (Supplemental Table S3).
Eighty-two percent (982/1194) of dogs with GBM demonstrated
at least one clinical sign attributable to biliary tract disease, andFig. 1. Flow diagram. A total of 1194 dogs with gallbladder mucoceles were included in
variables were included in univariable logistic regression analyses. bThe 10 most com
Miniature schnauzer, Bichon frise, Pomeranian, Border terrier, and Chihuahua). cOne dog
preceding cholecystectomy. dThe seven most commonly reported clinical signs (i.e. v
eBiochemical parameters (total serum/plasma bilirubin, cholesterol, and triglyceride co
resulted in missing data for these variables. fTime (days) from initial recognition of clinica
in the univariable analyses (P < 0.20) were included in the initial multivariable model. T
observations.those most commonly reported (i.e. in more than >10% of dogs)
included vomiting 80.0% (786/982), lethargy 46.7% (458/982),
anorexia 46.2% (454/982), diarrhea 18.3% (180/982), painful
abdomen 16.7% (164/982), hyporexia 11.2% (110/982), and jaundice
9.8% (96/982). The remaining distribution of clinical signs are
provided in Supplemental Table S4. Information on the duration of
clinical signs prior to cholecystectomy was available in 98.4% (966/
982) of dogs; the median time was 4 days (Q1, Q3, range; 2.0, 7.0,
1.0–730 days).
A total of 84.4% (1008/1194), 19.4% (232/1194), and 19.0% (227/
1194) dogs had cholesterol and triglyceride concentrations, or both
measured, respectively. Hyperlipidemia was identiﬁed in 90.8%
(585/644) dogs. Hypercholesterolemia was found in 55.4% (559/
1008) and hypertriglyceridemia was identiﬁed in 48.3% (112/232)
of dogs. Twenty-six percent (59/227) of dogs had normocholes-
terolemia and normotriglyceridemia. Total serum/plasma bilirubin
concentration was measured in 92.4% (1103/1194) of dogs, of which
the median was 2.3 times the upper limit of the reference interval
(Q1, Q3, range; 0.67, 11.2, 0.0–135).
Of the 10.1% (120/1194) of dogs diagnosed with hyperadreno-
corticism, 61.7% (74/120) were undergoing medical management
at the time of cholecystectomy. Of the 6.1% (73/1194) of dogs
diagnosed with hypothyroidism, all (73/73) were undergoing the study. aThere were no dogs excluded. Several potentially clinically signiﬁcant
mon breeds were included (i.e. Mixed breed, Shetland sheepdog, Cocker spaniel,
 did not have a clear distinction if clinical signs were present or absent in the 7-days
omiting, hyporexia, anorexia, jaundice, painful abdomen, diarrhea, and lethargy).
ncentrations) were performed at the discretion of the attending clinician, which
l signs to cholecystectomy was missing in 16/982 clinical dogs. Signiﬁcant variables
he ﬁnal multivariable model retained signiﬁcant variables (P < 0.05) with 915 total
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(69/1194) of dogs diagnosed with DM, all (69/69) were undergoing
medical management at the time of cholecystectomy.
Death-in-hospital occurred in 15.0% (179/1194; 95% CI 13.0–
17.1%) of dogs that underwent cholecystectomy for GBM. Ninety-
six of these dogs were euthanased and 83 died. Death-in-hospital
occurred in 17.1% (168/982) of dogs that demonstrated clinical
signs attributable to biliary tract disease at the time of
cholecystectomy, compared to 4.7% (10/211) of dogs that were
subclinical. The one dog without a clinical status prior to surgery
available, died following cholecystectomy. Of the dogs that were
subclinical and had cholecystectomy performed for prophylactic
purposes in absence of a concurrent procedure 5.4% (6/112) had
death-in-hospital. The reason for euthanasia and cause for death
was reported for all (96/96) and 45.8% (45/83) of dogs, respectively
(Supplementary Table S5).
Total serum/plasma bilirubin concentration as a biomarker to predict
to death-in-hospital
The area under the ROC curve for total serum/plasma bilirubin
concentrations in relation to survival-to-discharge in dogs with
GBM was 0.64 (95% CI, 0.60–0.69). The optimal cutoff was 4.3 times
the upper limit of the reference interval, with a greater increase
being consistent with death-in-hospital. Using this cutoff, a
sensitivity of 0.61 (95% CI, 0.54–0.69) and a speciﬁcity of 0.63
(95% CI, 0.59–0.66) for the prediction of death-in-hospital was
achieved (Table 1).
Univariable analysis
Variables pertaining to patient signalment that were signiﬁcant
in univariate screening (P < 0.20; Table 2; Fig.1) for increased odds
of death-in-hospital included being neutered/spayed (OR, 1.69;
95% CI, 0.95–3.01; P = 0.072) and increasing age (OR, 1.14; 95% CI,
1.07–1.22; P < 0.001). Breeds with signiﬁcant associations included
reduced odds of death for Miniature schnauzers (OR, 0.27; 95% CI,
0.08–0.88; P = 0.030) and increased odds of death for Pomeranians
(OR, 1.67; 95% CI, 0.82–3.42; P = 0.159; Table 3).
Dogs with GBM that demonstrated clinical signs attributable to
biliary tract disease had signiﬁcantly greater odds of death than
subclinical dogs in a univariable analysis (OR, 4.20; 95% CI, 2.14–8.23;
P < 0.001; Table 4). Owner recognition of jaundice was associated
with increased odds of death-in-hospital (OR, 2.33; 95% CI, 1.40–
3.89; P = 0.01), whereas vomiting was associated with decreased
odds of death (OR, 0.52; 95% CI, 0.34–0.78; P = 0.001; Table 4). Total
serum/plasma bilirubin concentration (OR, 1.03; 95% CI, 1.02–1.04;
P < 0.001) and hyperadrenocorticism (OR, 1.68; 95% CI, 1.04–2.70;Table 1
Sensitivity and speciﬁcity of fold change, with respect to the upper reference
interval, of total serum/plasma bilirubin concentration at time of presentation for
prediction of death-in-hospital for dogs following cholecystectomy for gallbladder
mucocoele management using different cutoff values.
Cutoff (fold increase) Sensitivity 95% CI Speciﬁcity 95% CI
0.01 1.00 0.98–1.00 0.01 0.01–0.02
1.32 0.77 0.70–0.83 0.42 0.39–0.46
2.00 0.70 0.62–0.77 0.51 0.48–0.54
3.00 0.66 0.58–0.73 0.58 0.55–0.61
4.00 0.63 0.55–0.71 0.61 0.58–0.65
4.30 0.61 0.54–0.69 0.63 0.59–0.66
8.60 0.47 0.39–0.55 0.74 00.71–0.76
10.10 0.42 0.34–0.49 0.76 0.73–0.79
15.00 0.28 0.21–0.35 0.83 0.81–0.86
20.20 0.19 0.14–0.26 0.88 0.86–0.90
71.67 0.01 0.00–0.04 1.00 0.98–1.00
CI, conﬁdence interval.P = 0.035; Table 5) were associated with increased odds of death-in-
hospital, but hyperlipidemia, hypercholesterolemia, duration of
clinical signs, and presence of other endocrinopathies were not
associated with odds of death (Table 5; Fig.1)
Multivariable analysis
Variables selected from screening that remained statistically
signiﬁcant (P < 0.05) in the ﬁnal multivariable regression
model included age (OR 1.17; P < 0.001), Pomeranian breed (OR
2.46; P = 0.029), presence of owner-identiﬁed jaundice (OR 2.12;
P = 0.011), quantitative increase in total serum/plasma bilirubin
concentration (OR 1.03; P < 0.001), and concurrent hyperadreno-
corticism (OR 1.94; P = 0.026) all increasing the odds of death, and
presence of vomiting decreasing the odds of death (OR 0.48;
P = 0.001; Table 2–5; Fig.1).
Discussion
This international, multi-center study included over 1000 dogs,
making it the largest GBM study to date. This study investigated
important variables with clinical plausibility to impact survival-to-
discharge including time from initial recognition of clinical signs to
cholecystectomy, presence or absence of clinical signs attributable
to biliary tract disease, presence of hyperlipidemia, total serum/
plasma bilirubin concentration, age, sex, breed, and presence of
endocrinopathy (i.e. DM, hyperadrenocorticism, hypothyroidism).
The results from this study indicate that the continuous variables
total serum/plasma bilirubin concentration and age, as well as the
categorical variables concurrent hyperadrenocorticism, Pomera-
nian breed, and owner recognition of jaundice at the time of initial
evaluation, were associated with increased odds of death.
Unexpectedly, owner recognition of vomiting at the time of
evaluation conferred a protective effect in our population. Lastly,
while increasing total serum/plasma bilirubin concentration was
associated with increased odds of death in this study, it proved to
be a poor biomarker to predict death.
Hyperbilirubinemia is a preoperative risk factor for death in
dogs undergoing biliary surgery and total serum/plasma bilirubin
concentrations predict a shorter survival time in Shetland
sheepdogs with gallbladder disease and in dogs with acute and
chronic hepatopathies (Aguirre et al., 2007; Amsellem et al., 2006;
Dereszynski et al., 2008; Ferguson et al., 2011; Gomez Selgas et al.,
2014; Kilpatrick et al., 2016; Lester et al., 2016; Poldervaart et al.,
2009). Likewise, total serum/plasma bilirubin concentration in the
present study conferred a signiﬁcant increase in odds of death-in-
hospital. Hyperbilirubinemia in dogs with GBM likely reﬂects more
severe or progressive disease with the presence of complications
such as gallbladder rupture, pancreatitis, partial or complete
extrahepatic bile duct obstruction, signiﬁcant functional hepato-
biliary disease, or endotoxin-induced (cholestasis of sepsis), which
have the potential to compromise survival after cholecystectomy
(Buote et al., 2006; Jaffey et al., 2018; Mayhew et al., 2002; Wang
and Yu, 2014). The aforementioned variables were not evaluated in
this study but warrant future investigations to better understand
the pathogenesis and impact hyperbilirubinemia has on survival in
dogs with GBM. While increasing total serum/plasma bilirubin
concentrations proved to be signiﬁcantly associated with death in
this study, its utility as a clinically reliable biomarker to predict
death was unacceptably poor. In other words, increasing total
serum/plasma bilirubin concentrations in dogs with GBM can be
interpreted as a negative prognostic indicator but cannot be relied
upon to predict outcome.
Dogs with GBM that demonstrated clinical signs attributable to
biliary tract disease at the time of cholecystectomy had 4.2 times
the odds of death than dogs that were subclinical in a univariable
Table 2
Results of univariable analyses related to signalment and ﬁnal multivariable model for association with death-in hospital. Variables associated with death-in hospital (P
< 0.20) in univariable analyses were included in initial multivariable regression analysis. Variables signiﬁcantly associated with death-in hospital (P < 0.05) were retained in
the ﬁnal multivariable regression analysis.
Signalment Variable Univariable Univariable Multivariable Multivariable
OR (95% CI) P-value OR (95% CI) Pb
Sex Female: 93/612 (15.2%) Male: 86/582 (14.8%) 1.02 (0.73–1.41) 0.925
Neutered status Neutered: 162/1042 (15.6%) Entire: 17/152 (11.2%) 1.69 (0.95–3.01) 0.072a
Age (years) Continuous (range 2–17) 1.14 (1.07–1.22) <0.001a 1.17 (1.08–1.26) <0.001
OR, odds ratio; CI, conﬁdence interval.
a P < 0.20 in univariable analysis and included in initial multivariable regression analysis.
b P < 0.05 in ﬁnal multivariable regression analysis.
Table 3
Results of univariable analyses related to the 10 most frequent breeds and ﬁnal multivariable model for association with death-in hospital. Variables associated with death-in
hospital (P < 0.20) in univariable analyses were included in initial multivariable regression analysis. Variables signiﬁcantly associated with death-in hospital (P < 0.05) were
retained in the ﬁnal multivariable regression analysis.
Breed (10 most frequent) Yes No Univariable Univariable Multivariable Multivariable
OR (95% CI) P-value OR (95% CI) P-value
Mixed breed 25/188 (13.2%) 154/1006 (15.3%) 0.93 (0.58–1.50) 0.768
Shetland sheepdog 19/126 (15.1%) 160/1068 (15.0%) 1.10 (0.65–1.88) 0.730
Cocker spaniel 11/74 (14.9%) 168/1120 (15.0%) 0.92 (0.47–1.83) 0.821
Miniature schnauzer 3/63 (4.8%) 176/1131 (15.6%) 0.27 (0.08–0.88) 0.030a
Bichon frise 6/58 (10.3%) 173/1136 (15.2%) 0.59 (0.24-1.42) 0.240
Beagle 7/54 (13.0%) 172/1140 (15.1%) 0.84 (0.37–1.93) 0.687
Pomeranian 11/48 (22.9%) 168/1146 (14.7%) 1.67 (0.82–3.42) 0.159a 2.46 (1.10–5.50)b 0.029
Border terrier 8/41 (19.5%) 171/1153 (14.8%) 1.58 (0.65–3.87) 0.315
Chihuahua 3/36 (8.3%) 176/1158 (15.2%) 0.51 (0.15–1.69) 0.269
Shih tzu 4/34 (11.8%) 175/1160 (15.1%) 0.72 (0.24–2.11) 0.547
OR, odds ratio; CI, conﬁdence interval.
a P < 0.20 in univariable analysis and included in initial multivariable regression analysis.
b Confounding present: Pomeranian breed confounded by variables of jaundice and vomiting.
Table 4
Results of univariable analyses related to clinical signs and ﬁnal multivariable model for association with death-in hospital. Variables associated with death-in hospital (P
< 0.20) in univariable analyses were included in initial multivariable regression analysis. Variables signiﬁcantly associated with death-in hospital (P < 0.05) were retained in
the ﬁnal multivariable regression analysis.
Clinical sign Present Absent Univariable Univariable Multivariable Multivariable
OR (95% CI) P-value OR (95% CI) Pb-value
Time clinical (days) Continuous (range 0–135) 0.99 (0.99–1.00) 0.450
Any sign 168/982 (17.1%) 10/211 (4.7%) 4.20 (2.14–8.23) <0.001a Collinear with jaundice/vomiting
Jaundice 29/96 (30.2%) 139/882 (15.8%) 2.33 (1.40–3.89) 0.001a 2.12 (1.19–3.77) 0.011
Hyporexia 23/110 (20.9%) 145/868 (16.7%) 1.23 (0.72–2.17) 0.451
Painful abdomen 25/164 (15.2%) 143/814 (17.6%) 0.85 (0.52–1.40) 0.531
Anorexia 78/454 (17.2%) 90/524 (17.2%) 1.05 (0.73–1.50) 0.785
Diarrhea 36/180 (20.0%) 132/798 (16.5%) 1.19 (0.78–1.82) 0.419
Vomiting 121/786 (15.4%) 47/192 (24.5%) 0.52 (0.34–0.78) 0.001a 0.48 (0.31–0.75) 0.001
Lethargy 71/458 (15.5%) 97/520 (18.7%) 0.80 (0.56–1.14) 0.214
OR, odds ratio; CI, conﬁdence interval.
a P < 0.20 in univariable analysis and included in initial multivariable regression analysis.
b P < 0.05 in ﬁnal multivariable regression analysis.
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model, the presence of clinical signs (present/absent) lost
signiﬁcance when adjusted for speciﬁc clinical signs. The ﬁnal
multivariable model indicated that owner recognition of jaundice
was associated with 2.1 times the odds of death. The sclera and skin
have detectable icterus when serum bilirubin is >51.3–68.4 mmol/L
[>3–4 mg/dl] in dogs (Willard and Twedt, 2012). Therefore, the
magnitude of hyperbilirubinemia was likely severe if untrained
dog owners were capable of recognizing it and as identiﬁed in our
study, increasing total serum/plasma bilirubin concentration was
associated with increased odds of death. Unexpectedly, dog owner
recognition of vomiting was associated with 0.46 times the odds of
death than when vomiting was not reported. It is possible that dogs
evaluated for GBM without vomiting had more advanced disease.This interesting ﬁnding warrants additional investigation. The
clinical progression of dogs with incidentally discovered GBM is
poorly understood as is the impact of elective cholecystectomy on
survival in these dogs (Clemente et al., 2017; Kesimer et al., 2015).
Moreover, the long-term beneﬁt of conservative medical therapy in
dogs with GBM is scarce. One retrospective study found that none
of the 15 dogs with hyperadrenocorticism treated with trilostane
for 6 months had resolution of GBM (Kim et al., 2017). However,
there is a report that describes GBM resolution in two dogs
following medical management (Walter et al., 2008). Therefore,
the ﬁnding that once clinical signs develop survival decreases
suggests prospective studies evaluating the impact of early surgical
intervention for incidentally discovered GBM on survival are
warranted.
Table 5
Results of univariable analyses related to clinicopathological ﬁndings/comorbidity and ﬁnal multivariable model for association with death-in hospital. Variables associated
with death-in hospital (P < 0.20) in univariable analyses were included in initial multivariable regression analysis. Variables signiﬁcantly associated with death-in hospital (P
< 0.05) were retained in the ﬁnal multivariable regression analysis.
Clinicopathological ﬁndings/comorbidity Present Absent Univariable Univariable Multivariable Multivariable
OR (95% CI) P-value OR (95% CI) Pb-value
Fold change in total serum/plasma bilirubin Continuous (range 0–135) 1.03 (1.02-1.04) <0.001a 1.03 (1.01–1.04) <0.001
Hyperlipidemia 77/585 (13.2%) 12/59 (20.3%) 0.62 (0.29–1.31) 0.210
Hypertriglyceridemia 19/112 (17.0%) 15/120 (12.5%) 1.61 (0.69–3.79) 0.273
Hypercholesterolemia 74/559 (13.2%) 67/449 (14.9%) 0.93 (0.64–1.35) 0.695
Diabetes mellitus 13/69 (18.8%) 166/1125 (14.8%) 1.39 (0.73–2.66) 0.315
Hypothyroidism 12/73 (16.4%) 167/1121 (14.9%) 1.20 (0.62–2.30) 0.595
Hyperadrenocorticism 27/120 (22.5%) 152/1074 (14.2%) 1.68 (1.04–2.70) 0.035a 1.94 (1.08–3.47) 0.026
OR, odds ratio; CI, conﬁdence interval.
a P < 0.20 in univariable analysis and included in initial multivariable regression analysis.
b P < 0.05 in ﬁnal multivariable regression analysis.
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GBM include Shetland sheepdog, Cocker spaniel, Miniature
schnauzers, and Border terriers (Aguirre et al., 2007; Allerton
et al., 2018; Jaffey et al., 2018). Further, one study reported that
Shetland sheepdogs with GBM formation were 9.3 times more
likely to have been treated with imidacloprid than Shetland
sheepdogs without GBM (Gookin et al., 2015). However, to the
authors’ knowledge, previous studies have not identiﬁed breed
associations with survival in dogs with GBM. Pomeranian breed
dogs had 2.3 times the odds of death than other breeds with GBM
in the present study. A speciﬁc pattern for cause of death in the
Pomeranians in our study could not be established because the
majority experienced cardiopulmonary arrest of unknown etiolo-
gy. However, of the Pomeranian dogs that were euthanased or died,
the most common reasons were hypoxemia and refractory
hypotension. Pomeranians are one of the most common breeds
affected by tracheomalacia, which could have contributed to post-
operative hypoxemia and refractory hypotension (Buback et al.,
1996; Macready et al., 2007). Future studies are needed to
investigate the cause for increased odds of death in Pomeranian
dogs with GBM.
Advancing age was associated with increased odds of death-in-
hospital in our study, consistent with many different studies
investigating risk factors for diseases in dogs (Hanson et al., 2007;
Mattin et al., 2018). Survival studies in veterinary literature are
subject to the confounding variables that inﬂuence euthanasia. It is
possible dogs with advanced age in this study were more likely to
develop a severe complication related to accrued comorbidities
that were not evaluated in our study. However, it is also possible
that clinicians and dog owners perceived advanced age negatively
and opted towards euthanasia if complications arose. Therefore,
the authors caution against utilization of advanced age as a stand-
alone negative prognostic indicator in dogs with GBM.
A concurrent diagnosis of hyperadrenocorticism at the time of
cholecystectomy in dogs with GBM yielded an approximately 2-
fold increase in odds of death-in-hospital than dogs without a
diagnosis of hyperadrenocorticism. There are several possible
explanations for this ﬁnding. We did not determine the severity of
illness, duration of illness, remission status or evaluate for
evidence of iatrogenic hypoadrenocorticism in dogs with hyper-
adrenocorticism in this study. Additionally, dogs were categorized
as having hyperadrenocorticism only if identiﬁed before the time
of cholecystectomy. It is possible that the dogs with a pre-operative
diagnosis of hyperadrenocorticism had more severe hypercorti-
solemia and more advanced or severe disease for a longer period of
time, which prompted their earlier diagnosis. Only 10% of dogs in
this study had a pre-operative diagnosis of hyperadrenocorticism
and the majority of those dogs were being medically managed at
the time of cholecystectomy. This small subset of dogs madestatistical evaluation of the impact of medical management of
hyperadrenocorticism on outcome in dogs with GBM unreliable
and was not pursued. Hypercortisolemia in dogs with hyper-
adrenocorticism without medical management or poor control of
disease can result in several potential deleterious consequences
including hypercoagulability (Park et al., 2013; Rose et al., 2013),
decreased wound healing (Wang et al., 2013), and immune system
dysregulation (Mori et al., 2009). Conversely, medically managed
dogs could be susceptible to either relative or absolute iatrogenic
hypoadrenocorticism at the time of cholecystectomy. Eucortiso-
lemia or true hypocortisolemia could have produced a physiologic
syndrome similar to critical illness related corticosteroid insufﬁ-
ciency (i.e. a state of relative adrenal insufﬁciency), which has been
associated with decreased survival in critically ill dogs (Burkitt
et al., 2007). Future prospective studies are required to investigate
the role of medical management of hyperadrenocorticism in dogs
with GBM prior to cholecystectomy.
Performing cholecystectomy in people with acute cholecystitis
within 72 h of the onset of symptoms signiﬁcantly decreases
overall morbidity and mortality (Cao et al., 2016; Gonzalez-
Rodriguez et al., 2009; Gutt et al., 2013; Johansson et al., 2003;
Johansson et al., 2005; Kolla et al., 2004; Lai et al., 1998; Lau et al.,
2006; Saber and Hokkam, 2014). In contrast to people with acute
cholecystitis, time (days) from the initial recognition of abnormal
clinical signs to cholecystectomy was not associated with survival
in dogs with GBM in this study when evaluated as a continuous or
categorical variable. The problems associated with delayed
surgical intervention (i.e. >72 h) in people with acute cholecysti-
tis are speculated to arise from prolonged regional inﬂammation
and life-threatening complications including gallbladder perfo-
ration, bile peritonitis, pericholecystic abscess, and the develop-
ment of a biliary ﬁstula (Kimura et al., 2007). While acute
cholecystitis in people is not directly comparable to dogs with
GBM, it is reasonable to suspect the sequela of both diseases could
be similar. The reliance on dog owners’ perception of when
clinical signs started was subject to various uncontrolled
variables related to the dog owner (e.g. medical background,
perceptiveness, multiple owners with conﬂicting opinions, and
accurate memory). However, in the absence of a canine GBM
experimental model dependence on dog owners’ historical
perception of their dog’s clinical signs while a limitation, is
essential, and clinically applicable. As it is not possible to reliably
determine whether cholecystitis is present alongside GBM then
owners should be advised of a likely increased risk of adverse
outcome were cholecystitis present and cholecystectomy not
performed with urgency. The frequency of concurrent cholecys-
titis in dogs with GBM is reported to range from 9% to 68%
(median, 25%; Pike et al., 2004; Malek et al., 2013; Wennogle
et al., 2019; Rogers et al., 2019).
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retrospective nature. Outcome in the present study was deﬁned as
death-in-hospital, which might have underestimated the overall
death rate attributed to dogs with GBM undergoing cholecystec-
tomy. The inclusion criteria of gross and histopathologically
conﬁrmed GBM were intentionally strict to optimally investigate
the primary aims. This strict approach likely omitted dogs that did
not have histopathology performed, or died or were euthanased
intra- or post-operatively then had histopathologic evaluation
withdrawn. Not every dog in this cohort was screened for an
endocrinopathy or had the necessary biochemical parameters
evaluated to diagnose hyperlipidemia. On that note, the decision to
perform various types of diagnostics varied with clinician
preference. The decision to evaluate cholesterol and/or triglycer-
ides could have been biased towards grossly lipemic samples.
Biochemical parameters were evaluated using different analyzers
with various reference intervals. This was mitigated by evaluating
cholesterol and triglyceride in relation to the upper limit of the
laboratory reference interval and categorizing them as either
hypercholesterolemia or hypertriglyceridemia. Moreover, total
serum/plasma bilirubin concentration analyses were made based
on the fold change with respect to the upper limit of each
laboratory reference interval. Survival analyses in our study did not
include previously identiﬁed prognostic variables in dogs with
GBM including lymphocyte count (Crews et al., 2009), gallbladder
rupture (Jaffey et al., 2018), postoperative serum lactate concen-
trations, and postoperative hypotension, which was a limitation
(Malek et al., 2013). The inclusion of euthanized dogs in our
survival analyses was a limitation. It is possible some of these
dogs were euthanized for reasons unrelated to severity of disease
(e.g. owner ﬁnances, owner objection to treatment, or clinician
recommendation). Inclusion of dogs that were euthanized in the
death-in-hospital group precludes our ability to truly determine if
dogs with certain risk variables are more likely to die naturally. For
example, there might be an underlying perception by attending
clinicians that clinical signs coupled with hyperbilirubinemia in
this population is associated with a poorer outcome. Relaying this
perception to owners might have increased the likelihood of
euthanasia, when a portion of these dogs could have survived. A
prospective study that allows clinicians to provide a detailed
description of the circumstances leading to euthanasia would be
able to provide a better understanding of the link between some of
these variables and survival. However, despite the inherent biases
and data issues associated with a multi-center retrospective study,
the large volume of cases, and diverse geographic source of care
included make the conclusions robust.
Conclusions
The ﬁndings of the present study indicate that increased total
serum/plasma bilirubin concentration is a negative prognostic
indicator but is an unacceptably poor biomarker for predicting
death-in-hospital in dogs with GBM at the time of cholecystecto-
my. The presence of clinical signs attributable to biliary tract
disease at the time cholecystectomy yielded signiﬁcantly greater
odds of death-in-hospital than subclinical disease status in a
univariable analysis. In the ﬁnal multivariable model, owner
recognition of jaundice was associated with increased odds of
death-in-hospital. Pomeranian breed dogs were more likely to die
in hospital following cholecystectomy than other breeds with GBM
in our study. Concurrent hyperadrenocorticism was associated
with nearly a 2-fold increase in odds for death in this study. The
presence of comorbidities including hyperlipidemia, DM, hypo-
thyroidism, and time (days) from initial recognition of clinical
signs to cholecystectomy, were not associated with survival.Conﬂict of interest statement
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